Urotronic  ROBUST I Clinical Study  DSC016 Rev F 
Page [ADDRESS_561507] for translation SWT 
B 7-14-2016 Minor changes to the re quired evaluations in Table 6-2 
uncovered during the review of the CRF with Urotronic team. 
xRemove the term ‚Äúscreen‚Äù from title
xRemove cystoscopy requirement intraprocedure
xRemove VAS score after [ADDRESS_561508] the compliance window  at baseline to be -
30SWT 
C 9/12/2016 Changes made based on input from FDA 
1. Increase frequency of serum drug content for a
limited number of patients
2. Semen collection ‚Äì add baseline collection.
Change [ADDRESS_561509]
7. Define Endpoint 2: Urethral measurement as
3DVVDJHRIDIOH[LEOHF\VW RVFRSHWRGHWHUPLQH¬ï
Fr urethral caliber
If the 16F flexible scope would not pass, then a 14
Fr flexible rubber catheter will be inserted through
the treated section
8. Redefine 3 months success
9. Standardize catheterizati on ‚Äì all patients will be
catheterized for a minimum of [ADDRESS_561510] procedure.11. Change exclusion crite ria #12 from 2.5 mg/dl to 2
mg/dl
12. Add exclusion #24 ‚Äì BXO13. Modif
y inclusion #5SWT 
Urotronic  ROBUST I Clinical Study  DSC016 Rev F 
Page [ADDRESS_561511] in ‚ÄúTable 6-2: Scheduled Evaluations and
Follow UP‚Äù
2. Clarify POBU and DCB dilation should not exceed the
rated burst pressure of the balloon.
3. Allow bladder neck contracture4. Increase enrollment number5. Add reference to SAPSWT 
E 6-8-[ADDRESS_561512] be
¬ï)SULRUWRWUHDWPHQWZLWK'&%
3. Update Table 6.[ADDRESS_561513] urethrogram and/or
fluoroscopy during treatment procedure to beconsistent with narrative.  No change in requirements.
4. Update Table 6.[ADDRESS_561514]
5. Detailed guidance on DVIU procedure per physician
input
6. Increased # of study site fro m ‚Äúup to 3 clinical sites‚Äù
to ‚Äúup to 5 clinical sites‚Äù
7. Add ‚ÄúRetreatment‚Äù-  Section 6.58. Excluded patients with a suprapubic catheter9. Increased blood PK samples from 15 to 30 sub
jectsSWT 
F 8-10-2017 Adminstrative update only.  No change in patient selection 
or treatment.   
1. Rearrange the order of endpoi nts to be consistent with
SAP.  Delete section 3.3.10 as it is redundant.
2. Clarify section 6.5 that all retreatment data will be
pooled but a separate summary will also be provided
3. Section 8: Remove redunda nt description of analysis
and refer to SAP only.
4. Add a condition for excluding patients with a
suprapubic catheter
5. Specify the risks of paclitaxelSWT 
Urotronic  ROBUST I Clinical Study  DSC016 Rev F 
Page [ADDRESS_561515] 11, 2017 
DSC016 Rev F 
[STUDY_ID_REMOVED] 
Urotronic                                                     ROBUST I Clinical Study                               DSC016 Rev F
Page [ADDRESS_561516] N #[ADDRESS_561517] read this protocol and agree to adhere to the requireme nts. I will provide copi[INVESTIGATOR_442031] r my supervision and 
my hospi[INVESTIGATOR_98802]/Research Ethi cs Board (EC/REB). I will discuss this 
material with them and ensure  they are fully informed rega rding the conduct of the study 
according to this protocol, applicable re gulatory requirements, and hospi[INVESTIGATOR_15303]/REB
requirements.
I agree to and understand the ma terial presented in this pr otocol, and must not publicly 
disclose in any manner the design, results, or co nclusions of this inve stigation w ithout prior 
written consent from Urotronic. 
___________________________________ 
Clinical Site Name
___________________________________    _____________________ 
Site Principal Investigator [CONTACT_25444]
__________________________________ 
Site Principal Investigator[INVESTIGATOR_442032] I Clinical Study                               DSC016 Rev F 
 
Page 6 of 55                                                                                               Confidential Protocol Summary 
 
Title:   ROBUST 1 
Re-Establishing Flow Via Drug Coat ed Balloon For The Treatment Of 
Urethral Stricture Disease  
Objective:  The study described below is design ed to determine the safety and 
effectiveness for drug-c oated balloon (DCB).  
Study Design:  Single ar m, multicenter study 
Enrollment:  Up to [ADDRESS_561518] 
Population:  1. Male subjects ¬ï 18 years‚Äô old  
2. Visual confirmation of strictur e via cystoscopy or urethrogram 
3. Single lesion anterior urethral stri cture or bladder neck contracture 
less than or equal to 2 cm  
4. One to three (1-3) prior diagnosis an d treatment of st ricture treatments 
(including self-catheterization)  including DVIU, but no prior 
urethroplasty 
5. Significant symptoms of stricture such as frequency of urination, 
dysuria, urgency, hematuria, slow  flow, feeling of incomplete 
emptying, recurrent UTI's.   
6. IPSS score of 13 or higher  
7. Lumen diameter <12F by [CONTACT_442045] 
8. Able to complete validated questionnaire independently 
9. Qmax <10 ml/sec  
Follow-up: [ADDRESS_561519] (Mundy PROM) Score 
Endpoint [ADDRESS_561520] I Clinical Study                               DSC016 Rev F 
 
Page 7 of 55                                                                                               Confidential Endpoint 8 Paclitaxel conten t in blood, urine and semen 
Endpoint 9  Stress Urinary Incontin ence at <90 days and >90 days 
Study and Data 
Management: Libra Medical, Inc. 
[ADDRESS_561521] N, Suite 63 Minneapolis, MN [ZIP_CODE] Tel: [PHONE_9274] Fax: [PHONE_9275] Email: [EMAIL_8503] 
Study Monitors: Libra Medical, Inc. 
[ADDRESS_561522] N, Suite 63 Minneapolis, MN [ZIP_CODE] Tel: [PHONE_9274] Fax: [PHONE_9275] Email: [EMAIL_8503] 
Sponsor: Urotronic Inc 
[ADDRESS_561523] N #[ADDRESS_561524] OF CARE ................................................................................................................... 12  
1.4 HISTORY OF USE OF PACLITAXEL  ................................................................................................................. 13  
1.5 RATIONALE FOR STUDY  ............................................................................................................................. 14 
2 DEVICE DESCRIPTION ............................................................................................................ ......... 14  
3 STUDY OBJECTIVES  AND DESIGN ................................................................................................... . 15 
3.1 OBJECTIVE  .............................................................................................................................. ............... 15  
3.2 STUDY DESIGN  .............................................................................................................................. .......... 15  
3.3 STUDY ENDPOINTS  .............................................................................................................................. .... 16  
3.3.1  Endpoint 1: Rate of Treatment Rela ted Serious Complication .................................................. 16  
3.3.2  Endpoint 2: Improvement in IPSS (International  Prostate Symptoms Score) ............................ 17  
3.3.3  Endpoint 3: Stricture Recurrence Rate ...................................................................................... 17  
3.3.4  Endpoint 4: Improvement LUTS (Lower urinary tract symptoms) Voiding Construct (Mundy 
PROM) Score (Patient-reported outcome measure) ............................................................................... 17 
3.3.5  Endpoint 5: Change in IIEF (International  Index of Erectile Function) ....................................... 17  
3.3.6  Endpoint 6: Repeat Trea tment Rate ......................................................................................... 17  
3.3.7  Endpoint 7: Change in Qmax (Peak Flow  Rate) at 3 and 6 months .......................................... 17  
3.3.8  Endpoint 8: Paclitaxel content in blood, urine and semen ........................................................ 17  
3.3.9  Endpoint 9: Stress Urinary Incontinence at <90 days and >90 days ......................................... 17  
3.3.10  Endpoint 10: Treatment Failure at 90 days .............................. Error! Bookmark not defined.  
[ADDRESS_561525] QUESTIONNAIRES  ........................................................................................................................ 32  
7.1.1  USS Score ..................................................................................................................... ............. 32  
7.1.2  Mundy PROM .................................................................................................................... ........ 32  
7.1.3  IPSS (Standard) ............................................................................................................... .......... 33  
7.1.4  IPSS (Acute) .................................................................................................................. ............. [ADDRESS_561526] Pain Questionnaire .................................................................................................... ... 33  
7.2 UROFLOWMETRY  .............................................................................................................................. ...... 33  
7.2.1  Peak Flow Rate (Qmax) Me asurement ..................................................................................... [ADDRESS_561527] Void Residual Urine Volume .............................................................................................. 34 
7.3 FLEXIBLE CYSTOSCOPY  ..............................................................................................................................  34 
7.4 URETHROGRAM  .............................................................................................................................. ........ 34  
7.5 RUBBER CATHETER  .............................................................................................................................. .... 35  
8 STATISTICAL C ONSIDERATIONS .................................................................................................... .. 35 
8.1 STATISTICAL ANALYSES  ............................................................................................................................. 35 
9 DEFINITION OF ADVERSE EVENT(S) ................................................................................................  35 
9.1 TREATMENT RELATED SYMPTOMS  .............................................................................................................. 35  
9.2 URINARY RETENTION AND CATHETERIZATION  ............................................................................................... 36  
9.3 URINARY RETENTION DEFINITION  ............................................................................................................... 36  
9.4 OBSTRUCTIVE LUTS .......................................................................................................................... ...... 36  
9.5 CODING OR CLASSIFICATION OF AES ........................................................................................................... 37  
9.6 POTENTIAL ANTICIPATED ADVERSE EVENTS  .................................................................................................. 38  
9.7 DEFINITION OF SERIOUS ADVERSE EVENT (S) ................................................................................................. [ADDRESS_561528]( S) (UADE) .................................................................................. [ADDRESS_561529] ENROLLMENT PROCESS  ............................................................................................................ 45  
12.3 ETHICS COMMITTEE (EC)  / INSTITUTIONAL REVIEW BOARD (IRB) ............................................................... 45  
12.4 INFORMED CONSENT FORM (ICF) ......................................................................................................... 45  
12.5 CASE REPORT FORMS (CRF S) ............................................................................................................... [ADDRESS_561530] I Clinical Study                               DSC016 Rev F 
 
Page 10 of 55                                                                                               Confidential 12.7 REPORTS  .............................................................................................................................. ............. 47  
12.8 SPONSOR RESPONSIBILITIES  .................................................................................................................. 48  
12.8.1  Confidentiality ............................................................................................................... ....... 48  
12.8.2  Amending the Investigational Study Protocol ...................................................................... 49  
12.8.3  Protocol Deviations ........................................................................................................... ... 49  
12.8.4  Protocol Deviation Notificati on/Approval to EC/I RB/Sponsor before Implementation ....... [ADDRESS_561531] infections, 
prostatitis, urinary retention and kidney damage. There were  1.5 million office visits from 
1992 to 2000 in US for the treatment of urethral  strictures, and resu lted in $[ADDRESS_561532] I Clinical Study                               DSC016 Rev F 
 
Page 12 of 55                                                                                               Confidential  
  Figure 1-1: Characteristic Pattern for Urine Flow in the Presence of Stricture 
 
1.[ADDRESS_561533] form of treatment is urethral dilation using a balloon, or rigid dilators.  The 
normal urethral caliber is 24-26F at the external  urinary meatus, a little  wider in the penile 
urethra, and about 36F at the bulbar urethra.13  
The principle of urethral dilation is to stretc h the urethral stricture up or to disrupt it to 
restore the urethral caliber to normal or ther eabout.  Urethrotomy and dilation are equally 
effective with expected cure rate  of about 50% for short bulbar urethral strictures when first 
used.  The success rate of repeated procedure is lower13.   
When strictures recur, they usually do so with in weeks or months and almost always within 
two years.  The expected recurrence rate re ported are schematically summarized in Figure 
1-2. 

Urotronic                                                     ROBUST I Clinical Study                               DSC016 Rev F
Page 13 of 55                                                                                               Confidential        Figure 1-2: Stricture Recurrence Rate
The average time to recurrence for previously  treated stricture is [ADDRESS_561534] at 6 months, 
whereas the risk of failur e after 12 months was slight11.  
1.4 History of Use of Paclitaxel
Paclitaxel has been used extensively and successfully in drug-coated devices to reduce the 
rate of stenosis in vascular tissue.  Examples  of the devices coated with this drug and the 
dates of approval in the US are shown in Tabl e 1-1.  The improvement in restenosis rates 
led Urotronic to design a similar sy stem to treat urinary strictures.
Table 1-1: US Approved Pa clitaxel Coated Devices
Drug Coated Balloon US Approval Date 
[LOCATION_011] Taxus DES [ADDRESS_561535] inva sive treatment for strictures .  However, because of the 
nature of strictures, recurren ce of the stricture (50% - 75% ) following balloon dilation is  
common2.  When stricture recurs after balloon d ilation, treatment often progresses to more 
invasive treatments: internal urethrotomy is a slightly more invasive approach that involves an endoscopic incision of the stricture, but is not more effe ctive than dilation
8,9,10; 
urethroplasty is an open surger y for stricture disease that is  more effective but far more 
invasive than dilation or internal urethrot omy.  Urethroplasty is performed by a minority 
(~2%) of urologists and the vast majority of subjects are managed by [CONTACT_442046][INVESTIGATOR_014].  Any improvement in technique or  means of changing the natural history and 
progression of the disease would make a si gnificant clinical c ontribution.  The study 
described below is designed to determine the safety and effectiveness of the drug coated 
balloon (DCB).    
2 DEVICE DESCRIPTION 
 
Figure 2-1:  Urotronic 0.038‚Äù Pacl itaxel-Coated Balloon Catheter  
 
The Urotronic Drug Coated Balloon (DCB) is a 0.038‚Äù guidewire compatible over-the-wire 
catheter with a tapered atraumatic tip. The dist al end of the catheter  has a semi-compliant 
inflatable balloon coated  with a proprietary coating cont aining the drug paclitaxel and 
carriers that facilitates the drug‚Äôs transfer to the urethr al wall upon inflation.    
Paclitaxel is an anti-inflamma tory and anti-proliferative drug commonly used to prevent 
arterial restenosis. The drug coating covers only the balloon body.  Initially, the device will 
be available in one size only 24Fr diameter.   Urotronic believes this size will be sufficient 
to treat the majority of the stricture.  However, during the study, other sizes may be 
introduced if the need arises. 
The device has two radiopaque marker bands th at indicate the drug coated working length 
of the balloon under fluoroscopy.  The device is provided steril e, and is intended for single 
use only. 

Urotronic                                                     ROBUST I Clinical Study                               DSC016 Rev F 
 
Page 15 of 55                                                                                               Confidential 3 STUDY OBJECTIVES AND DESIGN 
3.1 Objective 
The study described below is designed to de termine the safety and effectiveness for drug 
coated balloon (DCB).  
3.[ADDRESS_561536] I Clinical Study                               DSC016 Rev F 
 
Page 16 of 55                                                                                               Confidential    
Figure 3-1: Study Treatment Flow Chart 
 
3.3 Study Endpoints 
3.3.1 Endpoint 1: Rate of Treatment Related Serious Complication  
This safety endpoint is defined as a compos ite device related seriou s complications at [ADDRESS_561537] I Clinical Study                               DSC016 Rev F 
 
Page 17 of 55                                                                                               Confidential x Device related format ion of fistula  
x Device related de novo severe urinary rete ntion lasting > 14 consecutive days‚Äô post-
treatment. 
x Device related Unresolved de novo stress urinary incontinence (requiring >1 
pad/day) at [ADDRESS_561538] 
3.3.2 Endpoint 2: Improvement in IPSS (Intern ational Prostate Symptoms Score) 
 
3.3.3 Endpoint 3: Stricture Recurrence Rate 
The definition of stricture recurrence is th e urethra lumen being < 14 F with or without 
recurrence of symptoms at 6 months.  The uret hra caliber will be measured as follows: 
‚Ä¢ 3DVVDJHRIDIOH[LEOHF\VWRV FRSHWRGHWHUPLQH¬ï)UX rethral caliber   
‚Ä¢ If the 16F flexible scope would not pa ss, then a 14 Fr flexible rubber 
catheter will be inserted through the treated section  
Note: Obstruction symptoms due to BPH (B enign Prostatic Hyperplasia) will not be 
considered a stricture recurrence. 
3.3.4 Endpoint 4: Improvement LUTS (Low er urinary tract sy mptoms) Voiding 
Construct (Mundy PROM) Score (Pat ient-reported outcome measure) 
3.3.5 Endpoint 5: Change in IIEF (Internati onal Index of Erectile Function) 
3.3.6 Endpoint 6: Repeat Treatment Rate 
This is defined as repeat surger y or treatment for urethral stri cture in the same location of 
the urethra. 
3.3.7 Endpoint 7: Change in Qmax (Peak Flow Rate) at [ADDRESS_561539] is only valid 
if the voided volume is greater than 125ml. 
3.3.8 Endpoint 8: Paclitaxel content in blood, urine and semen 
Measurements will be measured by [CONTACT_442047]. 3.3.9 Endpoint 9: Stress Urinary Incontin ence at <90 days and >[ADDRESS_561540] th e patient‚Äôs health is in jeopa rdy or treatment failure is 
suspected based on one or both of  the criteria above.  Obstructive symptoms due to other 
reasons (e.g. BPH, bladder neck constriction)  other than stricture is not considered a 
treatment failure. 
[ADDRESS_561541] is considered enrolled if: 
Urotronic                                                     ROBUST I Clinical Study                               DSC016 Rev F 
 
Page 18 of 55                                                                                               Confidential x Meet all the inclusion criteria  
x Does not meet ANY exclusion criteria 
x Provided informed consent 
x Introduced the investigational device 
4.1 Inclusion Criteria 
1. Male sXEMHFWV¬ï\HDUV¬∂ROG  
2. Visual confirmation of strictur e via cystoscopy or urethrogram 
3. Single lesion anterior urethr al stricture or bladder neck  contracture, less than or 
equal to 2.0 cm 
4. One to three (1-3) prior diagnosis and tr eatment of the same stricture (including 
self-catheterization) including DVIU (Dir ect Vision Internal Urethrotomy), but 
no prior urethroplasty 
5. Significant symptoms of stricture such  as frequency of urination, dysuria, 
urgency, hematuria, slow flow, feeling of incomplete emptying, recurrent UTI's.   
6. IPSS score of 13 or higher  
7. Lumen diameter <12F by [CONTACT_442045] 
8. Able to complete validated questionnaire independently 
9. Qmax <10 ml/sec  
4.[ADDRESS_561542] 6 months.   
13. Diagnosed with chronic re nal failure unless under hemo dialysis or has a serum 
creatinine level greater than 2 mg/dL 
14. Use of alpha blockers, beta blockers , OAB (Overactive Bladder) medication, 
anticonvulsants (drugs that prevent or reduce the severity and frequency of 
seizures), and antispasmodics where the dose is not stable.  (Stable dose is 
defined as having the same medication and dose in the last six months.)  
15. Use of Botox (onabotulinumtoxinA) in urin ary system within the last [ADDRESS_561543] I Clinical Study                               DSC016 Rev F 
 
Page 19 of 55                                                                                               Confidential 16. Presence of a penile implant, artificial urinary sphincter, or stent(s) in the 
urethra or prostate 
17. Known neurogenic bladder, sphincter abnormalities, or  poor detrusor muscle 
function 
18. Diagnosed with Lichen Sclerosus, or previous hypos padias repair  
19. History within the last 5 years of car cinoma of the bladder or prostate 
20. History of cancer in non-g enitourinary system, which is not considered, cured 
(except basal cell or squamous cell ca rcinoma of the skin).  A potential 
participant is considered cured if there has been no evidence of cancer within 
five years of randomization 
21. Any cognitive or psychiatric condition that  interferes with or precludes direct 
and accurate communication with the study investigator regarding the study or 
affect the ability to complete the study quality of life questionnaires 
22. 8QZLOOLQJWRXVHSURWHFWHGVH[IRU¬ïGD\VSRVWWUHDWPHQW  
23. Inability to provide legally effective Informed Consent Form (ICF) and/or 
comply with all of the required follow-up requirements 
24. Participation in other pre-market studies 
25. Stricture due to balanitis xerotica obliterans (BXO) 
 
4.[ADDRESS_561544] pool to be included in the 
study and the sites‚Äô ability to  perform the resear ch in compliance w ith GCP guidelines. 
In addition, the sites must be able to comply with any count ry-specific requirements as 
well as other requirements specified by [CONTACT_85338] r respective institutional ethics committees 
(EC).   
[ADDRESS_561545] experience in  performing cystoscopi[INVESTIGATOR_014] , treating strictures 
endoscopi[INVESTIGATOR_442033]/ or other male urolog ical therapi[INVESTIGATOR_014].  
Selected physicians will be trained in the use of the Urotronic DCB prior to enrolling subjects.  The primary investigator will ensu re that only trained sub-investigators who 
satisfy the physician selectio n criteria can perform any pa rt of the study interventional 
procedure.   
Healthcare professionals or site  staff that assist or perform the follow-up evaluations do not 
need to be trained on the use of the device but must be delegated and trained to perform the 
follow-up visit procedures. 
[ADDRESS_561546] I Clinical Study                               DSC016 Rev F 
 
Page 20 of 55                                                                                               Confidential consented.  The site may not in itiate any study specific (non-s tandard of care) procedures 
without first obtaining in formed consent.    
All baseline testing and evalua tions must be done as close to the time of treatment as 
possible and repeated if need ed.  A baseline urethrogram must be performed prior to 
enrollment.  Any required proce dures performed before obtaini ng informed consent as part 
of the standard of care may be used in lieu of the study tests as de scribed in Table 6-1.  
The following evaluations will be completed for all study candidates.   Evaluations 
performed within the screening window ma y be acceptable.  The required baseline 
evaluations prior to enro llment are shown below: 
 
Table 6-1: Screening Evaluations Conditions 
Evaluations Accepted interval 
prior to procedure 
(unless specified 
otherwise) Condition 
Medical history  Within 30 days Evaluation is complete and 
adequately documented in 
report for assessment 
Physical exam evaluation Within 30 days Evaluation is complete and 
adequately documented in report for assessment 
Uroflowmetry1 
x 9RLGHGYROXPHPXVWEH¬ïP/
or test must be repeated for all the uroflow tests) 
x Voiding time 
x Peak flow rate (Qmax)[ADDRESS_561547] be performed before 
F\VWRVFRS\RU¬ïGD\VDIWHUcystoscopy and no evidence of UTI 
The uroflow method used in 
the second screening test must 
be the same as that used in the 
follow-up tests. 
Post-void residual urine volume (PVR; 
may be measured by [CONTACT_442048]- and post-treatment) 
 Within [ADDRESS_561548] be performed before 
F\VWRVFRS\RU¬ïGD\VDIWHU
cystoscopy and no evidence of UTI 
The PVR method used during 
screening must be the same as that used in the follow-up tests. 
Blood analysis 
x Complete blood cell count 
(CBC) 
x Blood urea nitro gen  (BUN) Within [ADDRESS_561549] I Clinical Study                               DSC016 Rev F 
 
Page 21 of 55                                                                                               Confidential Evaluations Accepted interval 
prior to procedure 
(unless specified 
otherwise) Condition 
x Serum creatinine 
x Alanine aminotransferase 
(ALT) 
x Drug Analysis 
 
Urine analysis 
x Sugar  
x Protein  
x WBC/RBC  
x Bacteria  
x Drug analysis  
x UTI Within [ADDRESS_561550] abstain from 
ejaculation 48 hours prior to 
semen collection 
Urethral Stricture Score (USS) Within [ADDRESS_561551] questionnaires  
x Mundy PROM  
x International Prostate 
Symptoms Score (IPSS) - 
Standard 
x International Index of Erectile 
Function (IIEF) 
x VAS Pain Scale Within [ADDRESS_561552] documented 
negative infection before 
enrolling and before taking the IPSS Mundy PROM at 
baseline 
Screening flexible cystoscopy  Within 2 months prior 
to enrollment Prior cystoscopy before 
enrollment is acceptable only if video is available for viewing 
Screening urethrogram (recorded)  Within 30 days prior 
to enrollment Prior urethrogram before 
enrollment is acceptable only if video is available for view 
Current or prior (up to 6 months) medication consumption Prior to enrollment A list of current and prior 
medication is required to determine if the dose is stable.  
Urotronic                                                     ROBUST I Clinical Study                               DSC016 Rev F 
 
Page [ADDRESS_561553] Enrollment 
Only subjects who meet the inclusion/exclusion criteria will be eligible to be enrolled and 
participate in the study.   
6.3 Concomitant Therapy 
Therapy (medication and non-medication ther api[INVESTIGATOR_014]) not restricted by a protocol 
requirement may be used during the study for the treatment or prevention of disease or to 
maintain good health. However, the subjects should not take concomitant medications that 
affect the urinary symp toms which might confound the study result.   
Standard dose of antibiotic is required to be administered before and after treatment. 
6.[ADDRESS_561554] I Clinical Study                               DSC016 Rev F 
 
Page 23 of 55                                                                                               Confidential    
Figure 6-1: Treatment Algorithm 
 

Urotronic                                                     ROBUST I Clinical Study                               DSC016 Rev F 
 
Page [ADDRESS_561555] infection (UTI) is indicated, the patient must be treated until the infection is 
cured before the study procedure. Oral NSAID or low dose aspi[INVESTIGATOR_442034]. 
 6.4.2 DCB Treatment 
The DCB should be prepared per the Instructions for Use (IFU ).  A summary is provided 
below.  If the summary is different from th e IFU, follow the instruction for the IFU. 
 Predilation 1. Perform a baseline urethr ogram if one was not reco rded within [ADDRESS_561556] uncoated balloon (POBU), plain old 
balloon urethroplasty).  Do not exceed ra ted burst pressure of the balloon.  If 
the stricture is not dilatable ( Dilatable is defined as stricture diameter post 
prHGLODWLRQLQFUHDVHE\¬ï 20F by [CONTACT_442049] n), the subject will be treated per DVIU prior to DCB treatment. 
6. If DVIU is indicated (see Figure 6-1); perform DVIU in 3 positions 
(approximately: 12 o‚Äôclock, 5 o‚Äô clock and 7 o‚Äôclock).   
7. Perform a urethrogram.  If the lumen is  <20F, perform predilation with an 
uncoated balloon.  Record lumen size with urethrogram.   
DCB Treatment 
8. Ensure that the urethra is flushed with saline and fill the bladder with saline 
before introduction of the DCB. 
9. Position the DCB across the predilated or DVIU treated stricture with the 
cystoscope proximal to th e balloon (away from the bladder) to visualize the 
proper placement of the balloon across th e stricture.  Leave the balloon in 
position uninflated for a minimum of  [ADDRESS_561557] I Clinical Study                               DSC016 Rev F 
 
Page 25 of 55                                                                                               Confidential 11. Inflate the balloon with a 50/[ADDRESS_561558] the 
inflation pressure. 
13. Remove the device(s).   
14. Collect urine sample (2nd void): 
a. Ask subject to void or palpate the bladder to allow about 1 cup (100 
‚Äì 150ml) of fluid to fl ow out of the urethra to flush any residual 
coating particles. This is recognized as the 1st void  
b. Then ask subject to void or palp ate the bladder again, collect the 
urine sample for about 100 ml or any remaining residual fluid for 
analysis. This is recognized as the 2nd void.   
15. Insert a 12-14 Fr Foley catheter (provi ded by [CONTACT_456]) for at least [ADDRESS_561559] be inflat ed at the target stricture to the 
recommended pressure for a minimum of  5 minutes with saline/contrast.   
x After dilation with DCB, no instrumentation can be passed through the stricture 
acutely with the exception of the Foley cathete U¬î)VL]HZKHQPHGLFDOO\
needed. 
x Use only the lubricious Foley ca theter provided by [CONTACT_456]. 
 
6.4.4 In-Hospi[INVESTIGATOR_442035]-steroidal anti-inflammatory drugs (N SAIDs) are recommended together with the 
use of antibiotic.   
 Blood PK (Pharmacokinetics) Samples 
For subjects (up to 30), who agr eed to be part of the PK c ohort, a total of [ADDRESS_561560] blood sample at 
baseline, then the next 6 blood samples (#2 - #7 ) will be drawn prior to discharge.  The 8th 
blood sample will be drawn post discharge at th e [ADDRESS_561561] DVIU, or ha ve the 2nd study procedure (Retreatment), 
will be asked to participate in the PK test.                    
 
Urotronic                                                     ROBUST I Clinical Study                               DSC016 Rev F 
 
Page 26 of 55                                                                                               Confidential Time points of blood sample collection: 
   # of 
Samples  Time points Approximate 
Compliance Window* 
1.  Baseline  - 30 da ys of procedure 
2.  0 hr  + 25 min 
3.  1 hr + 30 min 
4.  3 hrs ¬± 1 hr 
5.  5 hrs ¬± 1 hr 
6.  10 hrs ¬± 2 hrs 
7.  24 hrs ¬± 4 hrs 
8.  5 days ¬± 1 day 
The definition for ‚Äú0 hour‚Äù is post-procedure soon after collecting the urine sample.  
 Sexual Activities 
All subjects must be counseled about se xual activities post treatment as follows: 
x All patients will be asked to ABSTAI N from ALL sexual activities including 
masturbation for [ADDRESS_561562] may undergo a retreatme nt procedure at any point af ter the 3-month follow-up or 
before the 6-month follow-up vi sit, if the retreatment is recommended by [CONTACT_442050]: 
1. Treatment was not successful  and subject still experien ced retention and continue 
to meet the inclusion and exclusion criteria  
2. Initial DCB treatment was abandoned or  truncated due to discomfort, poor 
visibility or incorrect pla cement of DCB.  In this in stance, retreatment can be 
performed prior to the [ADDRESS_561563] continue to meet the initi al inclusion/exclusion criteria to be 
eligible for retreatment. 
All retreatment subjects will have the stricture predilated with DVIU prior to DCB 
treatment.  Only one retreatment is allowed for each subject.  The safety and effectiveness 
data collected post-retreatment will be pooled with the other subjects for analysis but the 
retreatment cohort data will also be summarized and provi ded separately.  Retreated 
Urotronic                                                     ROBUST I Clinical Study                               DSC016 Rev F 
 
Page [ADDRESS_561564]-procedure, 5 days, 14 days, 30 
days, 3 months, 6 months and 12 months‚Äô post-procedure.   
Annual evaluation of the stricture treatment  may be followed for up to [ADDRESS_561565] I Clinical Study                                DSC016 Rev  F 
 
Page 28 of 55                                                                                                   Confidential Table 6-2: Scheduled E valuations and Follow UP 
 Baseline Intra-
Procedure  Pre-
Discharge 5 days 14 days 30 days 3 
Months 6 and 12 
Months Annually for 
up to 5 years Unschedul
ed Visit 
Compliance 
Window -30 days NA NA ¬± 1 
day ¬± 2 days ¬± 5 days ¬± 14 
days ¬± 30 days ¬± 60 days NA 
Physical 
Examination ¬ó¬ó    ¬ó ¬ó ¬ó ¬ó ¬ó ¬ó 
Medication 
Usage Review ¬ó ¬ó ¬ó ¬ó ¬ó ¬ó ¬ó ¬ó  ¬ó 
Antibiotic ¬ó (pre-
procedure)  ¬ó        
Blood analysis 
(Complete blood 
cell count (CBC), 
Blood urea 
nitrogen  (BUN), 
Serum 
creatinine) ¬ó  ¬ó ¬ó       
Alanine 
aminotransferase 
(ALT) ¬ó   ¬ó       
Urine Analysis 
(sugar, protein, 
WBC/RBC, 
Bacteria (UTI))  ¬ó 
Within 7 days 
of procedure     ¬ó ¬ó ¬ó   ¬ó 
 Urine collection 
(drug analysis) ¬ó  ¬ó 
(2nd Void) ¬ó ¬ó ¬ó     
Urotronic                                                     ROBUST I Clinical Study                               DSC016 Rev F 
 
Page 29 of 55                                                                                               Confidential  Baseline Intra-
Procedure  Pre-
Discharge 5 days 14 days 30 days 3 
Months 6 and 12 
Months Annually for 
up to 5 years Unschedul
ed Visit 
Compliance 
Window -30 days NA NA ¬± 1 
day ¬± 2 days ¬± 5 days ¬± 14 
days ¬± 30 days ¬± 60 days NA 
Blood collection 
(drug analysis) ¬ó¬ó 1  ¬ó 1 
(multiple 
samples in 
24 hrs)  ¬ó 1       
Review Protected 
Sexual Activities    ¬ó ¬ó ¬ó ¬ó ¬ó 3 ¬ó 3 
(6 months 
only)    
Semen 
Evaluation ¬ó 
(sperm 
quality)    ¬ó 
(sperm 
and drug)  ¬ó 
(sperm 
and drug)  ¬ó  
(6 months 
for sperm 
only)    
USS ¬ó          
Mundy PROM  ¬ó    ¬ó ¬ó ¬ó ¬ó ¬ó ¬ó 
IPSS, IIEF ¬ó    ¬ó ¬ó ¬ó ¬ó ¬ó ¬ó 
VAS Pain score ¬ó  ¬ó ¬ó ¬ó ¬ó     
Qmax ¬ó    ¬ó ¬ó ¬ó ¬ó ¬ó ¬ó 
PVR ¬ó    ¬ó ¬ó ¬ó ¬ó ¬ó ¬ó 
 
Urethrogram ¬ó 
Record ¬ó [ADDRESS_561566]      ¬ó 
Record  ¬ó 
Record     
Urotronic                                                     ROBUST I Clinical Study                               DSC016 Rev F 
 
Page 30 of 55                                                                                               Confidential  Baseline Intra-
Procedure  Pre-
Discharge 5 days 14 days 30 days 3 
Months 6 and 12 
Months Annually for 
up to 5 years Unschedul
ed Visit 
Compliance 
Window -30 days NA NA ¬± 1 
day ¬± 2 days ¬± 5 days ¬± 14 
days ¬± 30 days ¬± 60 days NA 
 
Cystoscopy ¬ó¬ó 
Record       ¬ó 
Record 
(16F 
cystoscope)   ¬ó 
Record 
14F Rubber 
catheter urethral 
Lumen 
evaluation        ¬ó 
(If 16F 
scope failed 
to pass)   
Subject 
Satisfaction 
Questionnaire       ¬ó ¬ó   
AE Review ¬ó  ¬ó ¬ó 2 ¬ó ¬ó ¬ó ¬ó ¬ó ¬ó 
Note 
1 ‚Äì For the PK test, a total of 8 blood samples will be collected /patient. It requires patients to stay in the hospi[INVESTIGATOR_442036] [ADDRESS_561567]-procedurely. The blood draws at baseline and 5 days follow-up will be done accordingly, but no hospi[INVESTIGATOR_442037]. 
2 ‚Äì Pain /discomfort after the procedure is common and to be expected. Steps can be taken to minimize or eliminate pain /discom fort. It is at physician‚Äôs 
discretion, whether the pain /discomfort is an adverse event, or a normal healing process. 
3 ‚Äì  Review may be eliminated depending on the results of drug analysis from first 5 subjects. If so, a notice will be given to  the study sites by [CONTACT_2728]. 
4 ‚Äì Recorded Fluroscopy/urethrogram required before any intervention, during predil, post dil, during DCB, after DCB (fluorosco py only) 
 
Urotronic                                                     ROBUST I Clinical Study                                DSC016 Rev  F 
 
Page 31 of 55                                                                                                   Confidential 6.7 Unscheduled Follow-up Visits 
If subjects are seen for unscheduled/interim vi sits because of an AE, appropriate Case 
Report Form(s), including the AE CRF, will be completed if applicable.  At the 
investigator‚Äôs discretion, some of the evaluations and tests ma y be repeated if indicated.  
Sponsor requests that if any a dditional tests or procedures lis ted within this protocol are 
performed during an unscheduled visit the investigator provide the results on the 
Unscheduled Visit CRF. 
6.[ADDRESS_561568] 
and the method used (e.g., telephone contact, re gistered letter) must be documented in the 
subject‚Äôs records.   
If a subject misses one of the follow-up evalua tions, but is present at the subsequent 
follow-up, the subject can be read mitted into the study and quer ied retrospectively for basic 
information (e.g., AEs); however , the missed evaluation must be documented on a Protocol 
Deviation CRF.  The IPSS and other questionnaire s will be collected prospectively only.   
 
6.[ADDRESS_561569]‚Äôs withdrawal. 
6.11.[ADDRESS_561570]‚Äôs data may be exclude d from the analysis if  the subject is later found not to meet 
one or more major exclusion criteria.  However,  these subjects will continue to be followed 
per the requirements of their pa rticular arm unless instructed otherwise by [CONTACT_1201]/EC.  
The major exclusion criteria that would cause the withdrawal of the subjects‚Äô data are: 
 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page 32 of 55                                                                                                    Confidential 
 x Failure to obtain an informed consent prior to treatment; 
x Subject has severe BPH 
x Subject had bladder or sphi ncter dysfunctions or anythi ng else that will confound the 
results; 
x Subject had a psychiatric condi tion that prevents him from adequately answering the study 
questionnaires; or 
x Subject had a neuromuscular disord er that will confound the results. 
The decision to exclude the subject‚Äôs data from analysis will be documented in the CRF. 
6.11.[ADDRESS_561571]‚Äôs participation in the 
study will have a negative effect on the safety of the subject.  Data obtained up to the date 
of the subject‚Äôs withdrawal will be included in the study, if applicable.   
 
6.12 End of Study 
Subjects receiving the DCB treat ment may exit the study at th e end of the study (i.e., the 
study is discontinued by [CONTACT_1034]) or when th e subject has completed the 5-year follow-
up visit, whichever comes first, unless the subject opted to find  an alternative treatment.   
An End of Study CRF will be completed at the time the study is completed, discontinued, or 
lost to follow-up for each subject. 
 
[ADDRESS_561572] of treatment.  The major instruments and assessments administered are described in this section. 
7.1.1 USS Score 
The USS is a numerical score based on five components of an terior urethral stricture 
disease that help dictate operati ve decision-making: (1) urethral  stricture etiol ogy; (2) t otal 
number of strictures; (3) reten tion (luminal obliteration); (4 ) anatomic location; and (5) 
length. The USS describes the essential factors in determining surgical treatment selection 
for urethral stricture disease. The USS is a concise, easily applicable instrument that 
delineates the clinically significant features of urethral strictures. 
7.1.2 Mundy PROM 
This is a validated patient-reported outcome me asure (PROM) for anteri or urethral stricture 
surgery constructed from existing questionnaire.   This PROM defined a succinct, practical, 
and psychometrically robust PR OM designed specifically to quantify changes in voiding 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page [ADDRESS_561573].   
7.1.3 IPSS (Standard) 
The International Prostate Symptom Score (IPSS) contains the well-validated, highly 
reliable and responsive American Urologi cal Association symptom score (AUASS) 
assessment to identify the severity of BPH symptoms.  However, the symptoms of BPH and urinary stricture are very similar and has been used with strictures. 
The first seven questions in the IPSS addre ss frequency, nocturia, weak urinary stream, 
hesitancy, intermittence, inco mplete emptying, and urgency, a nd scored on a 6-point scale 
(0 to 5).  Although there are no standard reco mmendations for grading patients with mild, 
moderate, or severe symptoms, patients can be tentatively clas sified as follows: 0-7 mildly 
symptomatic, 8-19 moderately symptomatic, and 20-35 severely symptomatic. 
The IPSS also includes the following eighth que stion that is designed to assess the degree 
of "bother" associated with the subject's ur inary symptoms: "If you were to spend the rest 
of your life with your urinary condition just  the way it is now, how  would you feel about 
that?"  Answers range from "delighted" to "t errible" (0-6).  This  question correlates well 
with the overall BPH symptom score and summarizes the impact of urologic symptoms on quality of life. 
The standard IPSS will be administered at baselin e and at each follow-up visit, except the  
one week follow-up.   
7.1.4 IPSS (Acute) 
The acute IPSS is the same as the standard IPSS except that the que stions refer to the 
subject‚Äôs condition in the past week instead of the past month.  This IPSS will be 
administered at the one week follow-up visits  and if indicated, at  unscheduled visits. 
7.1.5 International Index of Erectile Function 
The International Index of Erectile Function (IIEF) is a standardized, validated, self-
administrated questionnaire that is used to a ssess the subject's erectil e function.  The Sexual 
Health Inventory for Men (SHIM) is part of the IIEF and cons ist of [ADDRESS_561574] 250 ml.  
Outcomes will be recorded for each qualified void on the case report forms and the strip 
recordings collected.  Voiding data will be ob tained with the subjects in the standing or 
sitting position, voiding into the uroflow instru mentation.  The uroflow meter will provide 
the following information: 
x 9RLGHGYROXPH¬ïPOUHTXLUHG for a valid test) 
x Peak flow rate, Qmax ( ¬ï5ml/sec to < 15 ml/sec to qualify) averaged over a 2 
second interval 
x Average flow rate 
x Voiding time 
7.2.1 Peak Flow Rate (Qmax) Measurement 
The recommendation for determining the Qmax re ading is to apply the [ADDRESS_561575] Void Residual Urine Volume 
Following uroflowmetry, residual urine volume in the bladder shall be assessed by [CONTACT_442051].   
7.3 Flexible Cystoscopy 
A screening flexible cystoscopy may be performed to confirm th e presence of stricture and 
to estimate the stricture condi tions (length and size) prior to  enrollment in the study.  The 
size and length is to be estimated without crossing the stricture at screening.  A post 
treatment flexible cystoscopy will be perform ed at the 6-month follow-up and subsequent 
follow up when cystoscopy is warranted.  
7.4 Urethrogram  
A retrograde urethrogram (RUG) is  taken to diagnose the strictur e, ensure the stricture is 
dilatable post predilati on, and to assess stricture recu rrence at follow-ups.  The general 
procedure steps are outlined below. 
x Position the patient and fluoros cope equipment so a lateral view, with the urethra in a 
single plane relative to the image is obtained. 
x Retract the foreskin and clean the tip of pe nis with betadine or antiseptic solution. 
x Liberally administer lidocaine jelly over the outside tip and shaft of a short 8F 
introducer sheath. 
x Place the introducer sheath into the tip of the penis.  Then place a markerwire into the 
introducer sheath down into the urethra.  Ensure the markers are visible in the 
fluoroscopic image. This is used for urethogram image dist ance calibration. 
x Attach a 50/50 saline/cont rast loaded syringe to  the introducer sheath. 
x Simultaneously inject the contrast and start a cine to capture the urethrogram. 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page [ADDRESS_561576] beginning to fill the bladder. 
7.5 Rubber Catheter 
Rubber catheters with known diamet ers may be used to estimate th e status of the stricture.   
 
8 STATISTICAL CONSIDERATIONS 
8.1 Statistical Analyses 
The data from the study wi ll be tabulated using de scriptive analyses.   
Descriptive analyses of all AEs and urinary sy mptoms will be provide d in the report.  In 
addition, the report will include tabulated results of study devi ations and device 
malfunctions. 
Details of the statistical analysis will be provi ded in the statistical analysis plan (SAP). 
 
9 DEFINITION OF ADVERSE EVENT(S) 
For purposes of this study, an adverse event (A E) is defined as any adverse change (i.e., de 
novo  or preexisting condition) from the subject‚Äô s baseline medical c ondition(s) occurring 
during the course of the study.  For the pur pose of AE documentation, the start of the 
course of the study is defined as any time after the treatment has been in itiated.  All AE‚Äôs 
will be recorded in the CRF whether considered procedure-related or not, and will be classified as described in Section 9.5.  
Pre-existing conditions will not be  reported as an AE unless there is an adverse change in 
that condition.  Any AE which resolved and then  recurred will be reported as a separate 
AE.   
An AE may be volunteered spontaneously by [CONTACT_3433] e subject or discovered as a result of 
questioning or physical examination by [CONTACT_442052]. 
  
9.[ADDRESS_561577] 
moderate to severe LUTS prior to treatment.  These symptoms are expected to continue and 
may even worsen slightly prior to improvement as  part of the healing process.  All reported 
LUTS will be documented in the CRF.  Other expected acute but transient worsening of symptoms from the treatment are dysuria, freque ncy of urination, urgenc y of urination, urge 
incontinence, hematuria, slowi ng of the urinary stream and acute retention as the tissue 
heals.  
Worsening or de novo LUTS, dysur ia or non-obstructive hematu ria that occur and resolve 
within 14 days of treatment that do not requ ire intervention (other than catheterization, 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page 36 of 55                                                                                                    Confidential 
 prophylactic antibiotic, anti-in flammatory medication, and pain medication) will not be 
considered an AE as these are expected and part of the healing process.  However, all 
treatment and related symptoms will be recorded in the CRF.  
Intervention as it relates to hematuria includes but is not limited to, hospi [INVESTIGATOR_059], the 
need to irrigate the bladder and urethra, or the need for transfusion therapy.   
 Common urinary symptoms will be considered  an AE if any of the following occur: 
a. Worsening or de novo LUTS requi ring intervention or persisting 
beyond [ADDRESS_561578] treatment; 
b. Worsening or de novo LUTS requiri ng hospi[INVESTIGATOR_442038], one standard  course of antibiotic, 
anti-inflammatory and/or pain medication; 
c. Hematuria that requires ir rigation or is  obstructive; 
d. Urinary tract infection defined as >10
5 CFU of a single organism plus 
symptoms localized to bladder. 
e. Urinary retention that did not resolv e within 10 days of treatment; or 
f. If de novo LUTS recurs after the sa me symptom is resolved and is 
considered clinically significant. 
 
9.[ADDRESS_561579] be 
evaluated for purposes of determining an AE.    
9.3 Urinary Retention Definition 
Urinary retention, also known as ischuria, is a total lack of ability to urinate.  It is 
sometimes referred to as acute urinary reten tion and typi[INVESTIGATOR_442039] a 
catheter or stent to avoid serious complications of the bladder and/or kidney. 
9.4 Obstructive LUTS 
Obstructive LUTS has some symp toms similar to Urinary Rete ntion.  Obstructive LUTS is 
usually a chronic condition and is sometimes referred to as chronic urinary retention.  
Symptoms of obstructive LUTS are: 
x Poor stream 
x Hesitancy 
x Terminal dribbling 
x Incomplete voiding 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page 37 of 55                                                                                                    Confidential 
 x Overflow incontinence (occurs in chronic retention) 
9.5 Coding or Classification of AEs 
Adverse events should be classified accordi ng to their underlying cause , if known (e.g., fever 
resulting from infection should be reported as ‚Äúinfection‚Äù).  Symptoms related to a diagnosis 
should not be reported as separate AEs.  In the above example, feve r is a symptom caused by 
[CONTACT_442053].   
Concomitant AEs that are unrelated (in the clinician‚Äôs judgment) should be reported as 
separate events. 
 AE determination is based on three levels of evidence: 
 
Level 1 ‚Äì final diagnosis Level 2 ‚Äì signs Level 3 ‚Äì symptoms  
Every effort should be made to collect Level [ADDRESS_561580]  level of severity, 
which is the final diagnosis (L evel 1).  A single AE should not  be reported as multiple AEs 
based on separate symptoms and signs. 
In cases where a diagnosis is not possible, AE determination should be based on the next 
highest level of evidence (i .e., Level 2: signs), followed  by [CONTACT_23805] (Level 3), if 
symptoms are all that are avai lable to the investigator.  
A corrective action (e.g. cathete rization) itself is not an AE but the reason of the 
catheterization may be an AE.  The AE de termination always should be based on the 
reason that a corrective action was taken.  Note: there may be multiple signs or symptoms 
representing only one AE.  Figure 9-[ADDRESS_561581] I Clinical Study                                   DSC016 Rev  D 
Page 38 of 55                                                                                                    Confidential 
 Complaint
Or Symptoms of 
AE?
Was 
there a medical
 exam?
Was 
there a final 
diagnosis?Record Sign 
as AE
(Level 2)
Record 
diagnosis as AE
(Level 1)Record AE as 
symptom
(Level 3)
Yes
YesNoNo
Did AE 
cause death, 
permanent injury, 
Hospi[INVESTIGATOR_442040]?
Report as SAEReport as 
AE
YesNo
 
Figure 9-1: AE Determination and Outcome Flowchart 
Example 1 (Diagnosis): prostatitis often has dysuria, urinary frequency, nocturia, difficult 
urination, pain in the groin, pe lvic area or genitals , painful ejaculation, and sometimes, flu-
like symptoms such as fever a nd chills.  If the diagnosis can  be established, prostatitis 
should be the AE, not the other symptoms.  Th e other symptoms may be listed with the AE. 
 Example 2 (Diagnosis): Urinary tract infecti on (UTI) often has dysuria, urinary frequency, 
urinary urgency, 
and hematuria.  If the dia gnosis of UTI can be established, the AE should 
be classified as an infection with sub-classi fication of UTI.  The symptoms may be listed 
with the AE.   
 Example 3 (Sign): Hematuria may lead to other symptoms, such  as dysuria, pain in flank 
and back, in addition to blood in the urine.  A blood clot may obstruct  the urethra and lead 
to urinary retention.  A disease diagnosis is pr eferred but a diagnosis may not be possible.  
In this case, hematuria (with clot retention) should be the AE clas sification/category, not 
the other symptoms. 
 
9.6 Potential Anticipated Adverse Events 
Potential anticipated adverse events are those th at may occur in associ ation with a stricture 
treatment or procedure, include those AEs lis ted below or reported in the literature 
associated with surgical or minima lly invasive stricture procedures : 
Surgical and Procedural Risks 
x Adverse reaction to the dr ug (paclitaxel) coating 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page 39 of 55                                                                                                    Confidential 
 Paclitaxel has been reported to prevent pr oliferation (growth of certain cells in the 
body). In this study, the purpose of using paclit axel on the device is to help prevent 
or reduce restenosis (stric ture reoccurring). However,  the risks of exposure to 
Paclitaxel include:  
o Chromosomal abnormalities a nd the risk of cancer  
o Fetal harm when a pregna nt woman is exposed  
o Anaphylaxis (allergic reaction) and hype rsensitivity reaction with paclitaxel 
intravenous infusion 
o Delayed healing of the wound in urethra due to the procedure 
o Potential effect on the liver and kidney s is unknown and have not been studied 
The amount of the paclitaxel delivered is mu ch lower than a single dose of chemotherapy 
provided to cancer patients and the drug a ppears to remain relatively localized. 
 
x Sepsis and infection 
x Fever 
x Perforation of urethra  
x Perforation of adjacent organs includi ng the rectum, bladder and GI tract  
x Urinary symptoms and adve rse events including: 
o Dysuria 
o Frequency 
o Urgency 
o Nocturia 
o Acute urinary retention 
o Incontinence 
o Sensation of not emptyi ng bladder completely 
o Urethritis 
o Irritative urinary symptom 
o Urethral injury causing false passage or adhesion 
o Urinary clot retention 
o Chronic pain in the pelvic area 
o Bladder spasm 
o Urethrorrhagia or  Hematuria with or wit hout clot in urethra 
o Discharge or cloudy urine 
o Discharge of tissue material during urination 
o Scarring of the urethral system 
o Urinary tract infection 
x Abscess (prostatic, bladder, scrotal) 
x Bladder problems or damage (reduced bladder sensation, spasms, bladder neck 
contracture, bladde r neck stenosis) 
x Bladder perforation or rupture 
x Damage to the urethral system 
x Worsening of strictur e or de novo stricture 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page [ADDRESS_561582] population are: 
x Blood pressure change during therapy 
x Arrhythmia 
x Flank pain 
x Blood loss (> 500 ml)  
x Adverse reaction to medication and anes thesia as listed in the labeling 
x Low blood pressure (hypotension) 
x High blood pressure (hypertension) 
x Fainting, dizziness, or blurred vision (vasovagal reaction, syncope) 
x Allergic reaction 
x Fatigue 
x Dyspnea 
x Confusion 
x Memory loss 
x Swelling or bruising (edema, hematoma) 
x Aneurysm ‚Äì thoracic and cranial 
x Low back pain 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page 41 of 55                                                                                                    Confidential 
 x Pneumonia 
x Collapsed lung  
x Pulmonary embolism 
x Pneumothorax 
x Upper respi[INVESTIGATOR_3765] 
x Cough 
x Sore throat 
x Apnea 
x Coughing up blood (hemoptysis) 
x Choking (aspi[INVESTIGATOR_1516]) 
x Venous thrombosis 
x Myocardial infarcti on, angina, ischemia 
x Cardiac arrhythmia 
x Stroke or transient ischemic attack 
x Brain damage 
x Headache 
x Depression 
x Perforation of or damage to the gastrointestinal tract 
x Abdominal pain 
x Constipation 
x Nausea or vomiting 
x Adverse reaction to medication 
 
9.7 Definition of Serious Adverse Event(s) 
An adverse event is considered to be a seri ous adverse event (SAE) if it resulted, or could 
result in, if not mitigated in: 
x Death  
x Is life-threatening 
x Requires the subject to be hospi[INVESTIGATOR_442041]   
x Results in persistent or significant disability/incapacity 
x Is considered an important medical event 
 
Important medical events that may not meet  one of the above definitions could be 
considered SAEs if they jeopard ize the health of the subject or  require surgical intervention 
to prevent one of the outcomes listed above.  An SAE may or may not be related to the 
study procedure.  
9.[ADDRESS_561583](s) (UADE) 
An unanticipated adverse device effect (UADE) is any serious adverse effect on the health 
or safety of a subject, any lif e-threatening problem or death ca used by, or associated with a 
device, if such effect, problem, or death was not previously iden tified in nature, severity, or 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page 42 of 55                                                                                                    Confidential 
 degree of incidence in the inve stigational plan (e.g., ICF, St udy Protocol, Instructions for 
Use (IFU), publications, etc.), or any other una nticipated serious problem associated with a 
device that relates to the rights, safety, or welfare of subjects.  
If an unanticipated adverse eff ect associated with the inves tigational device occurs, the 
investigator shall notify the Sponsor a nd the IRB/EC as soon as possible.   
The Sponsor will investigate the event and notify the authorities and IRB/EC and all other 
participating IRBs/EC and investigators.  Should the Sponsor determine that an 
unanticipated adverse effect presents an unreason able risk to all participating subjects, the 
Sponsor will suspend the clini cal investigation and notify all participating investigators, 
IRBs/EC, country regulatory bodies.  
9.[ADDRESS_561584] be described by (a) duration (start 
and resolution dates); (b) adjudi cated for severity; (c) relation ship to the study device; (d) 
action taken to resolve the event; (e) outcome  of the event; and (f) whether or not such 
event is considered to have been serious.  A dditional information, such  as procedural notes, 
treatment notes, or a si gned clinical summary, ma y be required as supporting 
documentation for the reported AE. 
During the study, all deaths must be reported to  the Sponsor within the period outlined in 
Table 12-1.  All deaths also should also be reported on the End of Study CRF.  A copy of 
the subject‚Äôs death records, me dical records for the events th at led to the subject‚Äôs death, 
and a death certificate (if avai lable) should be provided. 
 
9.10 Relationship of AE s to the Device 
A description of how an AE relates to the study procedure will be reported on the Adverse 
Event CRF and be determined by [CONTACT_442054]: 
 
x Definite :  The AE follows a reasonable tem poral sequence from the time of the 
index procedure, which includes AEs that  occur during the in dex procedure or 
during the follow-up period. 
x Probable :  The AE follows a reasonable tem poral sequence from the time of the 
index procedure, and the possibility can be excluded that factors other than the index 
procedure, such as underlying disease, c oncomitant drugs, or c oncurrent treatment 
caused the AE. 
x Possible :  The AE follows a reasonable temporal  sequence from the time of the index 
procedure and the possibility of index pr ocedure involvement cannot be excluded.  
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page 43 of 55                                                                                                    Confidential 
 However, other factors such as underlying diseas e, concomitant medications, or concurrent 
treatment are presumable. 
x Unlikely :  The AE has an improbable tempor al sequence from the time of the 
index procedure, or such AE can be reasonably explained by [CONTACT_1604], 
including underlying diseas e, concomitant medication, or concurrent treatment. 
x Not related : The AE has no temporal sequence fro m the time of the index procedure, 
or it can be explained by [CONTACT_1604], including unde rlying disease, concomitant 
medication, or conc urrent treatment. 
Those SAEs that are possibly related to the devi ce, the procedure, or the disease state being 
treated will be reviewed and adjudicated by [CONTACT_456].   
9.11 Device Failures, Malfuncti ons and Near Incidents 
Device failures or malfunctions will be reported to the sponsor by [CONTACT_145889].  If the 
failure or malfunction results in negative clinic al sequelae, the event shall be reported to 
the Sponsor within two (2) working days af ter the Investigator becomes aware of the 
device-related adverse event and reported to the IRB/EC (if required) within the IRB/EC 
required timeframe.  The malfunc tioning investigational devi ce involved in the incident 
should be returned to the Sponsor for evaluation.   
 
[ADDRESS_561585] s and wish to participate in the study will be 
assigned a unique identification code (ID ) using the format ‚ÄúXX-YYY‚Äù where: 
  XX = Institution Number, assigned by [CONTACT_214708] = Enrollment Number, assign ed by [CONTACT_442055] I Clinical Study                                   DSC016 Rev  D 
Page [ADDRESS_561586]‚Äô s initials will be used as an id entifier included on documentation 
submitted to the Sponsor. 
 
1.1 Central Database 
All study documentation will be co llected and compi[INVESTIGATOR_40177] a central  database.  Appropriate quality 
control measures will be establis hed to ensure accurate and comple te transfer of information from 
the study documentation to the central database 
 
12 STUDY RESPONSIBILITI ES AND MANAGEMENT 
12.1 Investigator Re sponsibilities  
Each investigator is responsible for ensuri ng the investigation is conducted according to 
all signed agreements, the study protocol, EC/IRB requirements,  and applicable laws and 
regulations.  Also, Investigator s may not begin enrollment un til Sponsor or its designee 
receives and approves (when necessary) the following documents: 
x Signed Investigator Agreement 
x Financial disclosure forms for all participating investigators 
x EC/IRB roster (or IRB registration number fr om the Office of Human Research Protection) 
x EC/IRB protocol and ICF approvals 
x Investigators‚Äô current curricula vitae (CV) 
x Signed Site Delegation Log 
 
It is acceptable for Investigator s to delegate one or more of the above functions to an 
associate or Co or Sub-I nvestigator, or a trained St udy Coordinator; however, the 
Investigator remains responsible for the pr oper conduct of the clin ical investigation, 
including obtaining and documen ting proper study informed c onsent, collecting all required 
data, submitting accurate and complete CRFs, etc. 
At each study site, appropriate procedures must be followed to maintain subject 
confidentiality according to appropriate local regulations.  Each site may have its own 
internal procedures or require ments for use and release of subject medical information in 
research studies.  Each Inve stigator is responsible for obt aining appropriate approvals, 
consents, or releases of medical information as  dictated by [CONTACT_442056]. 
The study is not transferable to other sites attended by [CONTACT_442057]/IRB and the Sponsor. 
 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page [ADDRESS_561587] appropr iately consent to 
participate in the study, as administrated by [CONTACT_442058]/IRB 
and Sponsor-approved informed consent form (I CF) prior to beginning any aspect of the 
study procedure or tests that are not standard of care for the s ite.  Investigational sites will 
be required to document the cons ent process within each enrolle d subjects medical record.  
Administering the questionnaires can be  done prior to signing the ICF. 
Only subjects who meet the inclusion/exclusion criteria, who signed the study enrollment 
informed consent will be cons idered enrolled in the study.  
Timely communication by [CONTACT_442059]. When enrol lment is close to the end of each phase, the 
following procedures will be implemented: 
 
x Before the subject signs the study ICF, the Study Coordinator must confirm the 
availability of an enrollment  slot.  A phone call to the S ponsor or Data Coordinating 
Center is the preferred method. 
x Immediately after the proce dure, the Study Coordinator mu st inform (phone call or 
fax or e-mail) the Sponsor or Data Coor dinating Center to co nfirm the subject‚Äôs 
eligibility and the co mpletion of the procedure.  A phone  call to the Sponsor is the 
preferred method. 
 
12.3 Ethics Committee (EC) / Institutional Review Board (IRB)  
Investigators must submit the study protocol to  their respective Ethics Committee (EC) and 
or Institutional Review Board (IRB) and obtain the EC‚Äôs/IRB ‚Äôs written approval before 
being allowed to conduct and participate in the study.  Each Investigator is responsible for 
fulfilling any conditions of a pproval imposed by [CONTACT_85338] r respective EC/IRB, such as regular 
reporting, study timing, etc.  Investigators will provide the Sponsor or its designee with 
copi[INVESTIGATOR_252473]. 
 
12.4 Informed Consen t Form (ICF) 
The Sponsor will provide a template informed  consent form (ICF) to each study site for 
EC/IRB submission.  The template may be mo dified to suit the requirements of the 
individual study site but the Spons or must pre-approve all changes to the IC F prior to initial 
submission to the EC/IRB.   
Each Investigator or assigned designee mu st administer this approved ICF to each 
prospective study subject, and obtain the s ubject's signature [INVESTIGATOR_1660] a legally-approved 
designee‚Äôs signature [CONTACT_442069].  The 
ICF must be obtained in accord ance with the applicable guidelines of the Declaration of 
Helsinki, or local regulations and laws, whichever represents the greater protection of the 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page [ADDRESS_561588] the 
study ICF. 
 
12.5 Case Report Forms (CRFs) 
The Sponsor will provide standardized cas e report forms (CRFs) for each individual 
subject.  The CRFs will be electronic (EDC, 21 CRF Part 11 compliant), and will be used 
to record study data, and are an integral part of the st udy and subsequent reports.   
The electronic CRFs for individual subject s will be provided by [CONTACT_124730] a web 
portal.  After the data have b een monitored and submitted, corre ctions will be initiated via a 
data query or Data Clarification Form (DCF) to be completed by [CONTACT_26271].  This 
DCF also will be done electro nically via the web portal.  Electronic CRFs must be 
approved and signed by [CONTACT_442060]/her 
electronic signature. 
 
12.[ADDRESS_561589] of the study investigation.  The final responsibil ity for maintaining 
such records remains with the Investigator .  These records incl ude, but not limited to: 
 
x All signed agreements; 
x IRB/EC approval letter(s); 
x Signed ICF; 
x Records of AEs, including supporting documents; 
x Records of protocol deviations , including supporting documents 
x Records showing receipt, use and dis position of all investigational devices, 
including: 
o Date, quantity, model and serial numbers of devices received, 
o Name [CONTACT_52943](s) who received, us ed or disposed of each device, 
o The number of devices returned to the Sponsor and the reason(s) for 
return; 
x All correspondence rela ted to the study; 
x Records of each subject‚Äôs case hi story, including study-required CRFs, 
signed ICF, all relevant observations of AEs, the condition of each subject 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page 47 of 55                                                                                                    Confidential 
 upon entering and during the course of the investigation, relevant medical 
history, the results of all diagnostic testing, etc.; 
x Study personnel visit log; 
x Signature [CONTACT_214728] a nd delegation log; and, 
x Any other records that applicable regulation requires to be maintained. 
 
12.7 Reports 
Table 12-1 lists those reports th at are the investigator's resp onsibility to deliver to the 
Sponsor.  Each study investigator must follow  the EC/IRB reporting requirements for their 
respective site.  If applicab le regulations or EC/IRB re quirements mandate stricter 
reporting requirements than t hose listed, the stricter requi rements must be followed. 
 
Table 12-1:  Reports Required fr om Investigators to Sponsor 
Type of Report Prepared by [CONTACT_976] [INVESTIGATOR_442042], EC/IRB 
 Within 10 working days of 
knowledge 
Death Sponsor, EC/IRB Writte n reports (e.g., via e-mail) 
within 48 hours 
SAE  Sponsor 
 
EC/IRB, if required Within 10 working days of 
knowledge  
Per EC/IRB requirement 
Device malfunction with 
clinical sequelae Sponsor 
 
EC/IRB, if required Within 48 hours via written 
communication.  Return the device to sponsor within 48 hours. 
Serious protocol deviations (e.g., ICF not obtained, to protect the life  or physical 
well-being of a subject in an emergency) Sponsor 
 
EC/IRB, if required Within 5 working days of knowledge 
Per EC/IRB requirement 
Withdrawal of EC/IRB 
approval Sponsor 
 Within [ADDRESS_561590] I Clinical Study                                   DSC016 Rev  D 
Page 48 of 55                                                                                                    Confidential 
 Type of Report Prepared by [CONTACT_976] [INVESTIGATOR_442043], EC /IRB As required by [CONTACT_177479]/IRB 
Final report Sponsor, EC/IRB Within  3 months of study completion 
or termination 
Note: Each IRB/EC may require more stringent reporting requirements th an those listed in  
          this table. 
 
12.8 Sponsor Responsibilities  
Urotronic, Inc. is the Sponsor  of this study.  The Sponsors responsibilities in the study 
include: 
x Selecting the Principal Investigator(s), all clinical investigators and study sites, and 
other consultants (e.g., monitors) who participate in the study. 
x Provide study protocol, device, and GCP tr aining to participating study sites, in 
quantities sufficient to  support study activitie s, per agreements executed with the 
study sites. 
x Select all qualified clinical Investig ators and study sites a nd other consultants (e.g., 
the study monitors) who pa rticipate in the study. 
x Provide financial support to each study site. 
x Follow/promote all regulatory standards pe r appropriate regulati ons for study sites, 
core laboratories, and other participants , and ensure compliance by [CONTACT_214724]. 
x Ensure completion of site monitoring of cl inical data at each clinical study site.  
x Retain ownership of all clin ical data generate d in this study, and control the use of 
the data for appropriate purposes only.   
x Review and approve publication of study results in the literature. 
 12.8.[ADDRESS_561591] ing to the country‚Äôs patient confidentiality 
regulations.  Data used in the analysis and reporting of this evalua tion will be used in a 
manner without identifiable reference to the subj ect.  Investigators will consent to visits by 
[CONTACT_2728]‚Äôs staff and its authorized represen tatives, as well as by [CONTACT_442061], to review the study subjects‚Äô medical records, including any test or 
laboratory data that might have been recorded on diagnostic test media (e.g., urethrogram).   
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page [ADDRESS_561592] be submitted to the EC/IRB for review and approval unless the changes do 
not affect the subject‚Äôs safety or the integrity of the data (e.g. administrative changes).  Any 
change that would require alteration to the IC F must receive approval from the applicable 
EC/IRB prior to implementation.  Following approval, any Investigational Protocol 
amendment must be distributed to al l protocol recipi[INVESTIGATOR_442044]. 
12.8.3  Protocol Deviations 
A protocol deviation/violation is generally an unplanned excurs ion from the protocol that is 
not implemented or intended as a systematic ch ange. An investigator fa iled to perform tests 
or examinations as required by [CONTACT_442062] e protocol, would be considered protocol 
deviations. These type of devi ations are reported to the spons or and in accordance with the 
EC/IRB policy. 
A Protocol Deviation CRF must be completed by [CONTACT_442063] r each study protocol deviation 
(e.g., failure to obtain informed consent, enrolling a subject who does not meet inclusion / 
exclusion criteria, no t performing required testing, mi ssed follow-up window, etc.).  An 
Investigator must notify the Sponsor and the reviewing EC/I RB of any deviation from the 
Study Protocol that was done to pr otect the life or physical we ll-being of a subject.  Such 
notice should be given as soon as possible, but no  later than five (5) working days after the 
emergency occurred. 
12.8.4  Protocol Deviation Notification/A pproval to EC/IRB/Sponsor before 
Implementation 
A protocol deviation may be a limited prosp ective exception to the pr otocol (e.g. agreement 
between sponsor and investigator to enroll  a single subject who does not meet all 
inclusion/exclusion criter ia due to out of window historical data).   
These types of deviations initiated by [CONTACT_442064]/IRB and the sponsor prior to  implementation.  This type of deviation 
can be used for historical data that is out of window (ie) due to date of screening visit. The 
objective is to prevent subjects from being subject to repeat a nd possible invasive testing.  
These type of deviations ar e only approved if they do not impact data integrity or put 
subjects at unreasonable risk. 
12.8.[ADDRESS_561593] I Clinical Study                                   DSC016 Rev  D 
Page 50 of 55                                                                                                    Confidential 
 3 months after ‚ÄúReady to Enroll‚Äù status, the Sponsor may elect to terminate the 
investigational site and allocate the slot to another can didate site.   
12.8.[ADDRESS_561594] ess as listed in the title page  of this document.  Monitors 
will ensure that the investigati on is conducted in accordance with:  
 
x The signed Investigator‚Äôs Agreement 
x The Investigational Plan  
x Appropriate laws and regulations  
x Any conditions of approval imposed by [CONTACT_230875]/IRB and/or other regulatory 
agencies  
The clinical study will be monitored according to the guidelines summarized below.  The 
sponsor may choose to perform random inspecti ons throughout the study as an element of 
quality assurance.  Investigators shall allo w auditing of their clinical investigation 
procedures.  
A study specific Monitoring Plan is created a nd implemented to standardize monitoring 
activities across centers and ensure human subjec t protection and verify data integrity.  The 
monitors shall receive study sp ecific and SOP training prior to conducting any monitoring 
visits.  Study monitors are selected based on th eir training, qualifications and experience to 
monitor the progress of an i nvestigation.  Study monitors ma y be Sponsor‚Äôs employees or 
representatives.  This study monitoring will include a site qualifica tion, study initiation, 
interim, and close out visits.  All study mon itors will be required to follow the Sponsor‚Äôs 
monitoring plan and mon itoring standard operating procedures (SOPs).  
The study monitoring will be done by [CONTACT_214710]: 
Libra Medical Inc [ADDRESS_561595] I Clinical Study                                   DSC016 Rev  D 
Page 51 of 55                                                                                                    Confidential 
 13.1.1  Monitoring Visit 
The following factors will be taken into acco unt when determining the frequency of the 
monitoring visits: subject accrual rate at each  center, total number of subjects enrolled at 
each center, and Clinical Investig ation Plan compliance at each center.  It is anticipated each 
site will be monitored at least once upon the completion of the 3-month follow-up visits for 
all enrolled subjects at the study site.  Monitors  will require direct acces s to subjects‚Äô medical 
records pertinent to the study (and study incl usion criteria), study management documents, 
regulatory documents and Subject  Informed Consent documents , as well as other potential 
applicable records not listed here.    Monitors may ensure the clinical investigators ha ve and continue to have  staff and facilities 
to conduct the clinical investigation safely and effectively.  Monitors may conduct the 
following monitoring activiti es throughout the study: 
 
x Verification that the current EC/IRB-a pproved informed consent was signed and 
dated by [CONTACT_442065]. 
x Verification of documentation in the subjec t‚Äôs record that informed consent was 
signed prior to initiation of  the study procedures and th at a copy of the signed 
and dated consent was pr ovided to the subject. 
x Source documentation verification by [CONTACT_442066]. 
x Verification that the device is being used according to the Clinical Investigation 
Plan, Instructions for Use and, all malfunctions/ IFU defi ciencies are reported. as 
required. 
x Verification that subjects me t study enrollment criteria. 
x Confirmation that the study is being conducted according to the Clinical 
Investigation Plan and applicable regulations. 
x Verification that study deviati ons are documented and reported. 
x Verification that the proce dures for recording and repor ting adverse events to the 
sponsor are followed. 
x Ensuring proper error correction. 
x Verification of training documentation of  all study personnel participating in 
study related activities. 
x Reviewing all correspondence and regul atory documents, including confirmation 
of IRB-approved Clinical Inves tigation Plan or amendments. 
x Resolution of outstanding issues and completion of assigned tasks will be 
documented by [CONTACT_85231]. 
 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page 52 of 55                                                                                                    Confidential 
 Each monitoring visit will be documented vi a a monitoring report a nd follow-up letter.  
The follow up visit letter shall be sent to the Investigator to documen t issues identified, 
corrective actions and if applicable preventativ e actions.  At subseque nt visits the issues 
resolved shall be documented in this  letter to demonstrate resolution. 
13.1.2  Study Closure 
Study closure is defined as a specific date th at is determined by [CONTACT_214713]/or 
regulatory requirements have been satisfied per the Clinical Investigation Plan (CIP) and/or 
by [CONTACT_442067]/IRB.  Study clos ure visits will be cond ucted at all enrolling 
clinical sites in order to re view record retention requireme nts with site personnel.  A 
telephone contact [CONTACT_442068] a study closure visit if  appropriate (e.g., low subject 
enrollment, recent monitoring visit, etc.)   
 
[ADDRESS_561596] N #[ADDRESS_561597] N, Suite 73 
Brooklyn Park, MN [ZIP_CODE] 
[PHONE_9274]  
[ADDRESS_561598] line extensions (e.g. larger di ameter or longer lengt h balloon) or design 
changes may be introduced into the study ba sed on feedback from investigators.  In 
addition, manufacturing changes may be introduced.  All desi gn and manufacturing process 
changes will be performed under the Sponsor‚Äôs design control process and fully tested to 
ensure that it meets specifications.  Significan t changes that may affect the device safety or 
efficacy will be provided to the EC/I RB as a supplemental application.    
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page [ADDRESS_561599] Vision Internal Urethrotomy 
EC/IRB Ethics Committee / Institutional Review Board 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
ICF Informed Consent Form 
ID Identification code 
IFU Instructions for Use 
IIEF International Index of Erectile Function 
IPSS International Prostate Symptoms Score 
LUTS Lower urinary tract symptoms 
NSAID Nonsteroidal anti -inflammatory drug 
OAB Overactive Bladder 
PROM Patient-reported outcome measure  
PSA Prostate Specific Antigen 
PVR Post Void Residual Urine Volum 
Qmax Peak Flow Rate Measurement 
RUG Retrograde Urethrogram 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page [ADDRESS_561600](s) 
USS Score Urethral Stricture Score 
UTI Urinary Tract Infection 
[ADDRESS_561601], Cottone JL, McIntyre WJ, Johnson DE Assessment 
of a New Transurethral Balloon Dilation Ca theter in the Trea tment of Urethral 
Stricture Disease Urology 2000; 55 (3) 
2. Heyns 1998 Heyns CF, Steenkamp JW, De Kock ML, Whitaker P. Treatment of 
male urethral strictures: Is  repeated dilation or inte rnal urethrotomy useful?  Journal 
of Urology 1998;160(2):356‚Äì8. 
3. Pansadoro 1996 Pansadoro V, Emiliozzi P In ternal urethrotomy in the management 
of anterior urethral stri ctures; long-term follow-up Journal of Urology  1996; 156:73 
4. Jezior 2002 Jezior JR and Schlossberg SM . Excision and primary anastomosis for 
anterior urethral stricture Urol Clin North AM , 2002; 29: [ADDRESS_561602] ricture; analysis of 168 subjects Journal of 
Urology  2002; 167: 1715 
6. Webster 1985 Webster GD, Koefoot RB,  and Sihelnik SA Urethroplasty 
management in 100 cases of ur ethral stricture: a rationa le for procedure selection 
Journal of Urology  1985; 134: 892 
7. Barbagli 1997 Barbagli G, Palminteri E, Ba rtoletti R, Selli C, and Rizzo M Long-
term results of anterior a nd posterior urethroplasty with  actuarial evaluation of the 
success rates Journal of Urology  1997; 158: 1380 
8. Albers 1996 Albers P, Fichtner J, Br√ºhl  P and M√ºller SC Long-term results of 
internal urethrotomy Journal of Urology  1996; 156:1611 
9. Charbit 1990 Charbit L, Mersel A, Beurt on D and Cukier J5-yea r treatment results 
of urethral stenosis using in ternal urethrotomy in adults Ann Urology  1990; 24: 66 
10. Jordan 2005 Jordan GH, Rourke KF Prima ry urethral reconstruction: the cost 
minimized approach to the bulbous urethral stricture Journal of Urology  2005; 173: 
1206 
11. Steenkamp JW, Heyns CF, and de Kock ML : Internal urethrotomy versus dilation 
as treatment for male uret hral strictures: a prospec tive, randomized comparison. J 
Urol 157: 98 ‚Äì101, 1997. Õí 
Urotronic                                                  ROBUST I Clinical Study                                   DSC016 Rev  D 
Page 55 of 55                                                                                                    Confidential 
 12. Stormont TJ, Suman VJ, and Oesterling JE: Newly diagnosed bulbar urethral 
strictures: etiology and outcome of various trea tments. J Urol 150: 1725‚Äì1728, 
1993.  
13. USS AR 2006: Management of Ur ethral Strictures                                     
Postgraduate Med J. 2006 Aug; 82(970): 489-493  
 